Trial Profile
A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs Sparsentan (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Sponsors Travere Therapeutics
- 17 Apr 2015 New trial record